AbbVie's latest quarterly results may have been solid, but the story that investors are increasingly focused on is no longer just its current blockbuster drugs. According to RBC Capital Markets, the next major catalyst for the pharmaceutical giant lies in its pipeline, with key data expected later this year.
Skyrizi and Rinvoq: Still Strong, But Facing Headwinds
RBC, an investment bank, noted that AbbVie's management sounded upbeat about the performance of its two key growth drivers: Skyrizi and Rinvoq. Skyrizi, a treatment for psoriasis and other inflammatory conditions, is holding up well even as new competitors enter the market. Rinvoq, used for rheumatoid arthritis and other autoimmune diseases, is also showing resilience.
However, the catch is pricing pressure. RBC expects this pressure to linger through 2027 and beyond, meaning that volume growth will have to do more of the heavy lifting to sustain revenue growth. This is a common challenge for drugmakers when their products face new rivals or when payers negotiate lower prices.
The Shift to Pipeline Data
With the near-term outlook for Skyrizi and Rinvoq becoming more predictable, investors are turning their attention to AbbVie's pipeline. The company is developing a new class of drugs called trispecific antibodies, which are designed to target multiple disease pathways at once. These could represent the next wave of innovation for AbbVie, potentially opening up new markets or improving upon existing treatments.
RBC highlighted that upcoming trispecific data, due later this year, is becoming a key focus for investors. This data could provide an early read on whether these experimental therapies have the potential to become future blockbusters, which would be crucial for AbbVie's long-term growth story.
What It Means for Investors
For everyday investors, this shift in focus is important because it signals that AbbVie's growth may increasingly depend on its pipeline rather than its current products. While Skyrizi and Rinvoq are still expected to contribute significantly, the pricing headwinds mean that their growth could slow over time. The success of the pipeline, particularly the trispecific candidates, could determine whether AbbVie can maintain its momentum in the coming years.
It's also worth noting that AbbVie has a history of navigating patent cliffs and competitive pressures. The company previously faced the loss of exclusivity for Humira, its former blockbuster, and successfully transitioned to Skyrizi and Rinvoq. Investors will be watching to see if the company can repeat that feat with its next-generation pipeline.
As with any pharmaceutical company, pipeline data is inherently uncertain. Clinical trials can fail, and regulatory approvals are never guaranteed. However, positive data could provide a significant boost to AbbVie's stock, while disappointing results could weigh on sentiment.
Broader Market Context
The focus on pipeline catalysts is not unique to AbbVie. Across the pharmaceutical sector, investors are increasingly valuing companies based on their ability to innovate and bring new drugs to market. This is especially true as many large drugmakers face patent expirations on their top-selling products in the coming years.
AbbVie's situation also highlights the broader theme of pricing pressure in the drug industry. Governments and insurers around the world are pushing for lower drug prices, which can squeeze profit margins. Companies that can offset these pressures with strong volume growth or by developing innovative therapies that command premium prices are often better positioned.
Looking Ahead
Investors will be closely monitoring AbbVie's upcoming pipeline readouts, as well as any updates on Skyrizi and Rinvoq's performance in the face of competition. The company's ability to execute on its pipeline strategy will be a key driver of its stock price in the months ahead.
For now, RBC's assessment suggests that AbbVie's current products are still on solid footing, but the real excitement lies in what comes next. As the company transitions from relying on its established blockbusters to nurturing its next generation of therapies, the stakes are high—and the data due later this year could be a pivotal moment.
For more on how drugmakers are navigating competitive pressures, see our coverage of AbbVie's recent earnings and outlook. And for a look at how other companies are handling similar challenges, check out RBC's take on Alnylam.
